Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

ProACT Post-Approval Study

NCT03767595 · tracked via the Priya Life Science USA tracker
Sponsor
Uromedica
Phase
Not applicable
Started
2019-02-19
Last updated
2026-10-06

Condition(s) studied

Stress Urinary Incontinence

Investigational drug(s) / intervention(s)

ProACT Adjustable Continence Therapy for Men

ProACT Adjustable Continence Therapy for Men: The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.

Study summary

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Eligibility

Sex
MALE
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subject is a male of at least 50 years of age. 2. Subject demonstrates stress urinary incontinence. 3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery. 4. Subject is willing and able to undergo surgical implantation of ProACT devices. 5. Subject is willing and able to comply with study-required follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies. 6. Subject is willing and able to sign the approved informed consent. 7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests). 8. Subject has a negative urine culture. 9. Subject has no known urogenital malignancy, other than previously treated prostate cancer. 10. Subject meets ONE of the following criteria: 1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL; 2. Baseline PSA \> 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA; 11. Physician determines subject to be a suitable surgical candidate. Exclusion Criteria: 1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy. 2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months. 3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo. 4. Subject has undergone radiation therapy in the prostatic area within the last 12 months. 5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity. 6. Subject has an atonic bladder. 7. Subject had, presently has, or is suspected of having bladder cancer. 8. Subject has untreated or unsuccessfully treated bladder stones. 9. Subject has detrusor sphincter dyssynergia. 10. Subject has known hemophilia or a bleeding disorder. 11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest). 12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Primary outcome measure(s)

  • Urethral Strictures — 5 years
    Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up.
  • Device Erosions — 5 years
    Cumulative incidence of ProACT device erosions over 5 years of follow-up.
  • Incontinence Quality of Life Questionnaire (I-QoL) — 5 years
    Results on Validated Incontinence Quality of Life Questionnaire

Trial sites (14)

FacilityCityRegionStatus
University of Southern California Los Angeles California Recruiting
Sutter Health Santa Barbara California Recruiting
University of Colorado Denver Colorado Recruiting
University of Florida Gainesville Florida Recruiting
Urological Research Network Corp Hialeah Florida Recruiting
Emory University Atlanta Georgia Recruiting
University of Kansas Medical Center Kansas City Kansas Recruiting
University of Michigan Ann Arbor Michigan Recruiting
CentraCare- St. Cloud Saint Cloud Minnesota Recruiting
CHI Health Research Omaha Nebraska Recruiting
Lehigh Valley Health Network Allentown Pennsylvania Recruiting
Allegheny Health Network Pittsburgh Pennsylvania Recruiting
Urology Partners of North Texas Research Institute Arlington Texas Recruiting
DHR Health Institute for Research and Development McAllen Texas Recruiting

More Uromedica trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03767595 on ClinicalTrials.gov ↗ ← All trials in the USA